yuelan/iStock Editorial via Getty Images
Johnson & Johnson (JNJ) on Sunday reported results from three clinical analyses showing lower mortality rates among patients receiving Impella heart pump support during high-risk coronary procedures compared with rates reported in the recent CHIP-BCIS3 clinical trial.
The analyses, presented at